SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for ...
BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback